Recordati SpA (REC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Recordati SpA (REC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9919
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Recordati SpA (Recordati), a subsidiary of Fimei SpA is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, dermatology, central nervous system disorders, musculo-skeletal disorders and analgesia and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over the counter (OTC) and non-prescription pharmaceuticals, antiinfectives and others. It also produces pharmaceutical chemicals, such as active pharmaceutical ingredients (APIs) and intermediates. Recordati sells its pharmaceuticals directly in the countries where it is present and through licensees in other places. Recordati is headquartered in Milano, Italy.

Recordati SpA (REC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Recordati SpA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Recordati Acquires Rights to Cystagon from Mylan 13
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14
Recordati Acquires Rights for Seloken from Astrazeneca 15
Recordati Rare Diseases Acquires North American Rights to Cystadane 16
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 17
Recordati Completes Acquisition Of Portfolio Of Products From Akvion For US$87 Million 19
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22
Private Equity 23
CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 23
Partnerships 25
Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27
Licensing Agreements 28
Recordati Enters into Licensing Agreement with MimeTech 28
Recordati Enters into Licensing Agreement with Meyer Hospital 29
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30
Recordati Enters into Licensing Agreement with Assistance Publique – Hopitaux de Paris 31
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 32
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 33
Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34
Plethora Enters into Licensing Agreement with Recordati for PSD502 36
Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38
Acquisition 39
Recordati Acquires Pro Farma for USD16.2 Million 39
Recordati Acquires Italchimici for up to USD145 Million 40
Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41
Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For US$122.5 Million 43
Recordati Completes Acquisition Of Farma-Projekt For US$21 Million 45
Recordati SpA – Key Competitors 46
Recordati SpA – Key Employees 47
Recordati SpA – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 51
Financial Announcements 51
Oct 30, 2018: Recordati announces sales and margin growth in the first nine months 2018. revenues +5.1%, ebitda +11.1%, operating income +9.6%,  net income +8.2%. interim dividend € 0.45 (+7.1%). 51
Jul 26, 2018: Recordati announces sales and margin growth in the first half 2018. Revenues +6.9%, operating income +14.1%, net income +11.7% 52
May 08, 2018: Recordati Announces Sales and Margin Growth in the First Quarter 2018 53
Mar 15, 2018: Recordati: Board Approves The 201 7 Accounts 54
Feb 08, 2018: Recordati: Preliminary 2017 Results Confirm Continued Growth of Sales and Profitability. Sales +11.6%, Operating Income +24.1%, Net Income +21.6% 57
Oct 26, 2017: Recordati: Very Good Results in the First Nine Months 2017. Continued Growth in Sales +11.8%, Operating Income +21.8%, Net Income +20.6%. Interim Dividend € 0.42 (+20%) 58
Jul 27, 2017: Recordati: Very Good Results In The First Half 2017. Continued Growth In Sales +10.7%, Operating Income +19.4%, Net Income +19.8% 60
May 04, 2017: Recordati: Excellent Results in the First Quarter 2017. Continued Growth in Sales +13.1%, Operating Income +19.0%, Net Income +19.9% 62
Mar 01, 2017: Recordati: Board Approves The 2016 Accounts. Sales € 1,153.9 Million (+10.1%), Operating Income € 327.4 Million (+17.6%) And Net Income € 237.4 Million (+19.4%). 2016 Dividend € 0.70 (+16.7%) 63
Feb 09, 2017: Recordati: Preliminary 2016 Results Confirm Continued Growth Of Revenues And Profitability 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
Recordati SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Recordati Acquires Rights to Cystagon from Mylan 13
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14
Recordati Acquires Rights for Seloken from Astrazeneca 15
Recordati Rare Diseases Acquires North American Rights to Cystadane 16
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 17
Recordati Completes Acquisition Of Portfolio Of Products From Akvion For US$87 Million 19
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22
CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 23
Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27
Recordati Enters into Licensing Agreement with MimeTech 28
Recordati Enters into Licensing Agreement with Meyer Hospital 29
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30
Recordati Enters into Licensing Agreement with Assistance Publique - Hopitaux de Paris 31
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 32
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 33
Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34
Plethora Enters into Licensing Agreement with Recordati for PSD502 36
Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38
Recordati Acquires Pro Farma for USD16.2 Million 39
Recordati Acquires Italchimici for up to USD145 Million 40
Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41
Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For US$122.5 Million 43
Recordati Completes Acquisition Of Farma-Projekt For US$21 Million 45
Recordati SpA, Key Competitors 46
Recordati SpA, Key Employees 47
Recordati SpA, Subsidiaries 48

List of Figures
Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Recordati SpA (REC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sharp HealthCare:企業の戦略的SWOT分析
    Sharp HealthCare - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Topaz Energy and Marine Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Topaz Energy and Marine Ltd (Topaz), a subsidiary of Renaissance Services SAOG, is an oil and gas company that offers offshore support vessels and marine solutions. The company's services include platform supply, anchor handling, emergency recovery and response and crew transfer. It operates …
  • Philippine National Bank:企業の戦略・SWOT・財務情報
    Philippine National Bank - Strategy, SWOT and Corporate Finance Report Summary Philippine National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Antero Resources Corporation (AR)-石油・ガス分野:企業M&A・提携分析
    Summary Antero Resources Corporation (Antero), formerly Antero Resources Appalachian Corporation, is an independent oil and natural gas company that carries out exploration, development, production and acquisition of natural gas, natural gas liquids (NGLs) and oil properties in the Appalachia Basin. …
  • Saint-Gobain Weber GmbH:企業の戦略・SWOT・財務分析
    Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report Summary Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • STR Holdings Inc:企業の戦略的SWOT分析
    STR Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Brunswick Corporation (BC):企業の財務・戦略的SWOT分析
    Brunswick Corporation (BC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Lafarge Malaysia Berhad (LAFMSIA):企業の財務・戦略的SWOT分析
    Summary Lafarge Malaysia Berhad (LMB), formerly Lafarge Malayan Cement Berhad is a construction company that manufactures and markets aggregates, ready-mixed concrete, cement, and related construction and building materials. The company offers cement products such as walcrete, rumah, phoenix, oil we …
  • Sandvik AB:企業の戦略・SWOT・財務情報
    Sandvik AB - Strategy, SWOT and Corporate Finance Report Summary Sandvik AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • United Therapeutics Corp (UTHR):医療機器:M&Aディール及び事業提携情報
    Summary United Therapeutics Corp (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (tre …
  • Citrix Systems Inc (CTXS):企業の財務・戦略的SWOT分析
    Citrix Systems Inc (CTXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • China Sunergy Co., Ltd.:企業の戦略的SWOT分析
    China Sunergy Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Futuren (FTRN)-エネルギー分野:企業M&A・提携分析
    Summary Futuren, formerly Theolia SA, is a wind energy producer that prospects, develops, constructs, installs and operates wind power projects. It specializes in designing and building onshore wind plants. Futuren conducts these operations for its own account as well as for third parties. The compa …
  • Curie Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Curie Institute is a cancer research foundation that operates cancer research institutes and hospitals and concentrates on the developing new treatments for cancer. The foundation carries out research in the areas of immunology, pharmachemistry, bioinformatics and systems biology, cell biolo …
  • Brokk AB:企業の戦略的SWOT分析
    Brokk AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Emgesa SA ESP:企業の戦略的SWOT分析
    Emgesa SA ESP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Rentschler Biotechnologie GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Rentschler Biotechnologie GmbH (Rentschler), a subsidiary of Dr. Rentschler Holding GmbH & Co KG is a contract development and manufacturing organization that develops and manufactures biopharmaceuticals. The organization offers bioprocess development, biomanufacturing, and consulting servic …
  • iX Biopharma Ltd (42C):企業の財務・戦略的SWOT分析
    Summary iX Biopharma Ltd (iX Biopharma) is a pharmaceutical company that provides that offers drug delivery and formulation. The company's pipeline product portfolio includes development of drugs for various indications such as opioid-sparing for acute, severe and chronic pain; male erectile dysfunc …
  • Energy XXI Gulf Coast Inc (EGC):石油・ガス:M&Aディール及び事業提携情報
    Summary Energy XXI Gulf Coast Inc (Energy XXI) is an oil and gas company that explores and develops oil and natural gas assets. The company’s projects include West Delta, South Timbalier, South Pass, Main Pass, and Ship Shoal. Its West Delta property is located 28 miles offshore of Grand Isle, Louis …
  • Allianz Global Assistance SAS:企業の戦略・SWOT・財務情報
    Allianz Global Assistance SAS - Strategy, SWOT and Corporate Finance Report Summary Allianz Global Assistance SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆